Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HY-PAM "25" vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydroxyzine pamoate is a piperazine antihistamine that acts as a histamine H1-receptor antagonist, thereby suppressing histamine-mediated responses in the skin and mucous membranes. Additionally, it exhibits anxiolytic and sedative properties through central nervous system depression via inhibition of subcortical regions.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Symptomatic relief of anxiety and tension associated with psychoneurosis,Adjunct in organic disease states with anxiety,Pruritus due to allergic conditions such as chronic urticaria, atopic and contact dermatoses
Hypertension
25 mg orally once daily, preferably at bedtime, for short-term treatment of insomnia.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Terminal elimination half-life 6-8 hours in healthy adults; prolonged to 12-18 hours in renal impairment (Cr Cl <30 m L/min) and in elderly patients.
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Primarily hepatic via CYP3A4 and CYP2D6 isoenzymes; major metabolite is cetirizine.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Primarily renal (60-70% unchanged drug), with 30-40% biliary/fecal elimination as metabolites.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
95-98% bound to albumin and alpha-1-acid glycoprotein.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
0.2-0.3 L/kg, indicating primarily plasma and extracellular fluid distribution.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral: 60-70% (due to first-pass metabolism); Rectal: 80-90%; Intramuscular: 100%.
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), use with caution; no specific dose recommendation available.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
For Child-Pugh Class A or B, dose reduction to 12.5 mg daily may be considered due to increased exposure; avoid use in Child-Pugh Class C (severe hepatic impairment).
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not established; contraindicated in pediatric patients due to lack of safety and efficacy data.
Not established; avoid use in children.
Start at 12.5 mg daily; maximum dose 25 mg daily due to increased sensitivity and risk of falls, cognitive impairment, and adverse effects.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
None
None
May cause QT prolongation, especially in patients with risk factors,Use with caution in patients with narrow-angle glaucoma, prostatic hypertrophy, or urinary retention,Central nervous system depressant effects may impair mental or physical abilities,Avoid concurrent use with alcohol or other CNS depressants,Use with caution in elderly patients due to increased sensitivity and anticholinergic effects
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Hypersensitivity to hydroxyzine or any component,Early pregnancy (first trimester) due to potential fetal harm,Porphyria (may precipitate attacks),Concomitant use with monoamine oxidase inhibitors
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
No significant food interactions known.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
HY-PAM 25 is a benzodiazepine. First trimester: Data suggest an increased risk of oral clefts (approximately 0.6% vs 0.4% background). Second trimester: Possible risk of other malformations, but data are limited. Third trimester: Chronic use may cause neonatal withdrawal, floppy infant syndrome (hypotonia, lethargy, feeding difficulties), and respiratory depression at delivery.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Benzodiazepines like HY-PAM 25 are excreted in breast milk. The M/P ratio is approximately 0.5-0.7. With short-acting agents and moderate doses, risk to infant is low but monitor for sedation and poor feeding. Avoid breastfeeding if high maternal doses or chronic use; consider alternative agent.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
Increased clearance and volume of distribution in pregnancy may require dose adjustment. For HY-PAM 25, consider increasing the dose by 20-30% in third trimester to maintain efficacy, but taper postpartum to avoid accumulation. Use lowest effective dose and avoid chronic use.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
HY-PAM '25' is a compounded topical formulation containing hydrocortisone 2.5%, pramoxine 1%, and aluminum acetate 0.25%. Use for acute inflammatory dermatoses with pruritus and exudation. Avoid prolonged use on intertriginous areas. Discontinue if signs of skin atrophy or secondary infection develop.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Apply a thin layer to affected areas 3-4 times daily.,Do not use on broken skin, deep wounds, or infected skin without medical guidance.,Avoid contact with eyes and mucous membranes.,Do not cover with bandages or dressings unless directed by your doctor.,Report any worsening of rash, burning, or signs of skin thinning.,Do not use for more than 2 weeks unless directed by your doctor.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HY-PAM "25" vs ALDORIL 25, answered by our medical review team.
HY-PAM "25" is a Antihypertensive Combination that works by Hydroxyzine pamoate is a piperazine antihistamine that acts as a histamine H1-receptor antagonist, thereby suppressing histamine-mediated responses in the skin and mucous membranes. Additionally, it exhibits anxiolytic and sedative properties through central nervous system depression via inhibition of subcortical regions.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HY-PAM "25" and ALDORIL 25 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HY-PAM "25" is: 25 mg orally once daily, preferably at bedtime, for short-term treatment of insomnia.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HY-PAM "25" and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HY-PAM "25" is classified as Category C. HY-PAM 25 is a benzodiazepine. First trimester: Data suggest an increased risk of oral clefts (approximately 0.6% vs 0.4% background). Second trimester: Possible risk of other malf. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.